Abstract
Diabetes mellitus is one of the most common endocrine disorders. It affects almost 6% of the world’s population, and its prevalence continues to increase. The causes of diabetes mellitus are multifactorial, and in the general population both genetic and environmental factors contribute evenly to its development. Several genes have been consistently associated with type 2 diabetes mellitus; however, it is not clear how many of those translate into increased cardiovascular disease risk. Recent evidence suggests that genetic variation at the CALPN10, FABP4, GK, GST, PPARA, and PPARG loci may confer higher cardiovascular disease risk in patients with type 2 diabetes mellitus. However, the evidence is scattered and inconclusive and its translation into practical clinical testing will require studies properly designed to examine not only simple genetic associations but also gene-gene and gene-environment interactions.
This is a preview of subscription content, access via your institution.
References and Recommended Reading
- 1.
Adeghate E, Schattner P, Dunn E: An update on the etiology and epidemiology of diabetes mellitus. Ann N Y Acad Sci. 2006, 1084:1–29.
- 2.
Hansen L, Pedersen O: Genetics of type 2 diabetes mellitus: status and perspectives. Diabetes Obes Metab 2005, 7:122–135.
- 3.
Harris F, Biswas S, Singh J, et al.: Calpains and their multiple roles in diabetes mellitus. Ann N Y Acad Sci 2006, 1084:452–480.
- 4.
Lefebvre P, Chinetti G, Fruchart JC, Staels B: Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 2006, 116:571–580
- 5.
Semple RK, Chatterjee VK, O’Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest 2006, 116:581–589.
- 6.
Barish GD, Narkar VA, Evans RM: PPAR delta: a dagger in the heart of the metabolic syndrome. J Clin Invest 2006, 116:590–597.
- 7.
Tobin JF, Freedman LP: Nuclear receptors as drug targets in metabolic diseases: new approaches to therapy. Trends Endocrinol Metab 2006, 17:284–290.
- 8.
Laclaustra M, Corella D, Ordovas JM: Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis 2007, 17:125–139.
- 9.
Yamauchi T, Kamon J, Waki H, et al.: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor (PPAR) deficiency and PPAR agonist improve insulin resistance. J Biol Chem 2001, 276:41245–41254.
- 10.
Guan HP, Li Y, Jensen MV, et al.: A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002, 8:1122–1128.
- 11.
Tonjes A, Scholz M, Loeffler M, Stumvoll M: Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with Pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 2006, 29:2489–2497.
- 12.
Doney AS, Fischer B, Leese G, et al.: Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol 2004, 24:2403–2407.
- 13.
Harris F, Biswas S, Singh J, et al.: Calpains and Their multiple roles in diabetes mellitus. Ann N Y Acad Sci 2006, 1084:452–480.
- 14.
Hanis CL, Boerwinkle E, Chakraborty R, et al.: A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet 1996, 13:161–166.
- 15.
Horikawa Y, Oda N, Cox NJ, et al.: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163–175.
- 16.
Goodarzi MO, Taylor KD, Guo X, et al.: Association of the diabetes gene calpain-10 with subclinical atherosclerosis: the Mexican-American Coronary Artery Disease Study. Diabetes 2005, 54:1228–1232.
- 17.
Makowski L, Hotamisligil GS: The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005, 16:543–548.
- 18.
Chmurzynska A: The multigene family of fatty acid-binding proteins (FABPs): function, structure and polymorphism. J Appl Genet 2006, 47:39–48.
- 19.
Humphreys P, McCarthy M, Tuomilehto J, et al.: Chromosome 4q locus associated with insulin resistance in Pima Indians. Studies in three European NIDDM populations. Diabetes 1994, 43:800–804.
- 20.
Weiss EP, Brown MD, Shuldiner AR, Hagberg JM: Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics 2002, 10:145–157.
- 21.
Galluzzi JR, Cupples LA, Otvos JD, et al.: Association of the A/T54 polymorphism in the intestinal fatty acid binding protein with variations in plasma lipids in the Framingham Offspring Study. Atherosclerosis 2001, 159:417–424.
- 22.
Galluzzi JR, Cupples LA, Meigs JB, et al.: Framingham Offspring Study: Association of the Ala54-Thr polymorphism in the intestinal fatty acid-binding protein with 2-h postchallenge insulin levels in the Framingham Offspring Study. Diabetes Care 2001, 24:1161–1166.
- 23.
Baier LJ, Sacchettini JC, Knowler WC, et al.: An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995, 95:1281–1287.
- 24.
Levy E, Menard D, Delvin E, et al.: The polymorphism at codon 54 of the FABP2 gene increases fat absorption in human intestinal explants. J Biol Chem 2001, 276:39679–39684.
- 25.
Stan S, Lambert M, Delvin E, et al.: Intestinal fatty acid binding protein and microsomal triglyceride transfer protein polymorphisms in French-Canadian youth. J Lipid Res 2005, 46:320–327.
- 26.
Weiss EP, Brown MD, Shuldiner AR, Hagberg JM: Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effects. Physiol Genomics 2002, 10:145–157.
- 27.
Damcott CM, Feingold E, Moffett SP, et al.: Variation in the FABP2 promoter alters transcriptional activity and is associated with body composition and plasma lipid levels. Hum Genet 2003, 112:610–616.
- 28.
Brouillette C, Bosse Y, Perusse L, et al.: Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate. J Hum Genet 2004, 49:424–432.
- 29.
Tuncman G, Erbay E, Hom X, et al.: A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease. Proc Natl Acad Sci U S A 2006, 103:6970–6975.
- 30.
Elosua R, Ordovas JM, Cupples LA, et al.: Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study. J Lipid Res 2006, 47:990–996.
- 31.
Doney AS, Fischer B, Lee SP, et al.: Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: A Go-DARTS study. Nucl Recept 2005, 25:3–4.
- 32.
Doney AS, Lee S, Leese GP, et al.: Increased cardiovascular morbidity and mortality in type 2 diabetes is associated with the glutathione S transferase theta-null genotype: a Go-DARTS study. Circulation 2005, 111:2927–2934.
- 33.
Marz W, Nauck M, Hoffmann MM, et al.: G(−30)A polymorphism in the pancreatic promoter of the glucokinase gene associated with angiographic coronary artery disease and type 2 diabetes mellitus. Circulation 2004, 109:2844–2849.
- 34.
Yamasaki Y, Katakami N, Sakamoto K, et al.: Combination of multiple genetic risk factors is synergistically associated with carotid atherosclerosis in Japanese subjects with type 2 diabetes. Diabetes Care 2006, 29:2445–2451.
- 35.
Ordovas JM: Genetic interactions with diet influence the risk of cardiovascular disease. Am J Clin Nutr 2006, 83:443S–446S.
- 36.
Corella D, Ordovas JM: Integration of environment and disease into ‘omics’ analysis. Curr Opin Mol Ther 2005, 7:569–576.
- 37.
Corella D, Ordovas JM: The metabolic syndrome: a crossroad for genotype-phenotype associations in atherosclerosis. Curr Atheroscler Rep 2004, 6:186–196.
Author information
Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ordovas, J.M. Genetic links between diabetes mellitus and coronary atherosclerosis. Curr Atheroscler Rep 9, 204–210 (2007). https://doi.org/10.1007/s11883-007-0020-9
Published:
Issue Date:
Keywords
- Liver Fatty Acid Binding Protein
- Intestinal Fatty Acid Binding Protein
- Pro12Ala Polymorphism
- Fatty Acid Binding Protein Gene
- High Cardiovascular Disease Risk